|
ZNF827 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.61210053587035E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.0142555118573E-13 |
| Normal-vs-Stage2 |
3.44460000001323E-06 |
| Normal-vs-Stage3 |
2.75890421619351E-11 |
| Normal-vs-Stage4 |
1.703803764741E-11 |
| Stage1-vs-Stage2 |
4.829200E-01 |
| Stage1-vs-Stage3 |
6.813700E-02 |
| Stage1-vs-Stage4 |
2.586100E-02 |
| Stage2-vs-Stage3 |
5.233500E-02 |
| Stage2-vs-Stage4 |
3.935700E-02 |
| Stage3-vs-Stage4 |
6.656000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.67969979539373E-10 |
| Normal-vs-AfricanAmerican |
2.599800E-04 |
| Normal-vs-Asian |
6.09910000282099E-08 |
| Caucasian-vs-AfricanAmerican |
2.695400E-01 |
| Caucasian-vs-Asian |
9.274000E-01 |
| AfricanAmerican-vs-Asian |
3.651600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.0999980360491E-11 |
| Normal-vs-Female |
9.4206997758306E-10 |
| Male-vs-Female |
8.279700E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.49582601649945E-12 |
| Normal-vs-Age(41-60Yrs) |
5.06816810741384E-13 |
| Normal-vs-Age(61-80Yrs) |
2.19809948021066E-10 |
| Normal-vs-Age(81-100Yrs) |
6.205300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.221400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.291800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.630400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.929800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.679000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.374200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.844790E-03 |
| Classical-VS-Follicular |
5.837600E-01 |
| Classical-VS-Other |
1.723250E-01 |
| Classical-VS-Normal |
5.43769995697829E-09 |
| Tall-VS-Follicular |
2.895500E-02 |
| Tall-VS-Other |
7.862400E-01 |
| Tall-VS-Normal |
8.62643290133747E-12 |
| Follicular-VS-Other |
2.665400E-01 |
| Follicular-VS-Normal |
8.16280043558493E-10 |
| Other-VS-Normal |
1.51968999999585E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.04787314778332E-13 |
| Normal-vs-N1 |
2.59150034764843E-10 |
| N0-vs-N1 |
1.910180E-01 |
|
|
